A list of stem cell therapy trial(s) currently underway that may potentially benefit patients with Usher syndrome. Please refer to the link under each trial for more information on that trial. Please be aware that all information provided are for informational purposes only, and are in no way endorsed or approved by Usher Syndrome Ireland.
Phase 1/2a
- ReNeuron are using hRPC (human retinal progenitor cells) technology to potentially reduce or halt further vision loss. They also believe that these hRPCs will integrate into the retina and possibly mature into photoreceptors thus possibly restoring vision. They are currently conducting a Phase I/IIa clinical trial in the US, UK and Spain with their hRPC therapy candidate for RP, independent of RP or USH type, so it may potentially benefit patients with Usher syndrome. More information can be found here: http://www.reneuron.com/products/hrpcs-for-retinitis-pigmentosa/
Phase 2b
- jCyte, is a stem cell therapy company that uses retinal progenitor cells (RPCs) in their treatment, and have recently reported promising results from its Phase 2b clinical trial of its therapy for people with retinitis pigmentosa (RP), Usher syndrome, and related conditions. The company plans to launch a Phase 3 trial for the treatment in 2021. More information can be found here: https://www.jcyte.com/pipeline/